» Articles » PMID: 24795635

The Iron Regulatory Capability of the Major Protein Participants in Prevalent Neurodegenerative Disorders

Overview
Journal Front Pharmacol
Date 2014 May 6
PMID 24795635
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

As with most bioavailable transition metals, iron is essential for many metabolic processes required by the cell but when left unregulated is implicated as a potent source of reactive oxygen species. It is uncertain whether the brain's evident vulnerability to reactive species-induced oxidative stress is caused by a reduced capability in cellular response or an increased metabolic activity. Either way, dys-regulated iron levels appear to be involved in oxidative stress provoked neurodegeneration. As in peripheral iron management, cells within the central nervous system tightly regulate iron homeostasis via responsive expression of select proteins required for iron flux, transport and storage. Recently proteins directly implicated in the most prevalent neurodegenerative diseases, such as amyloid-β precursor protein, tau, α-synuclein, prion protein and huntingtin, have been connected to neuronal iron homeostatic control. This suggests that disrupted expression, processing, or location of these proteins may result in a failure of their cellular iron homeostatic roles and augment the common underlying susceptibility to neuronal oxidative damage that is triggered in neurodegenerative disease.

Citing Articles

Gerstmann-Sträussler-Scheinker Disease Presenting as Late-Onset Slowly Progressive Spinocerebellar Ataxia, and Comparative Case Series with Neuropathology.

Stephen C, de Gusmao C, Srinivasan S, Olsen A, Freua F, Kok F Mov Disord Clin Pract. 2024; 11(4):411-423.

PMID: 38258626 PMC: 10982592. DOI: 10.1002/mdc3.13976.


Synthesis, physicochemical characterization and neuroprotective evaluation of novel 1-hydroxypyrazin-2(1)-one iron chelators in an cell model of Parkinson's disease.

Lewis F, Bird K, Navarro J, El Fallah R, Brandel J, Hubscher-Bruder V Dalton Trans. 2022; 51(9):3590-3603.

PMID: 35147617 PMC: 8886574. DOI: 10.1039/d1dt02604f.


Interaction between Hemin and Prion Peptides: Binding, Oxidative Reactivity and Aggregation.

DellAcqua S, Massardi E, Monzani E, Di Natale G, Rizzarelli E, Casella L Int J Mol Sci. 2020; 21(20).

PMID: 33066163 PMC: 7589926. DOI: 10.3390/ijms21207553.


Exploring the Use of Dimethyl Fumarate as Microglia Modulator for Neurodegenerative Diseases Treatment.

Rosito M, Testi C, Parisi G, Cortese B, Baiocco P, Di Angelantonio S Antioxidants (Basel). 2020; 9(8).

PMID: 32756501 PMC: 7465338. DOI: 10.3390/antiox9080700.


Iron Redox Chemistry and Implications in the Parkinson's Disease Brain.

Abeyawardhane D, Lucas H Oxid Med Cell Longev. 2019; 2019:4609702.

PMID: 31687080 PMC: 6803728. DOI: 10.1155/2019/4609702.


References
1.
Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

2.
Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan E, Adalsteinsson E . MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage. 2011; 59(3):2625-35. PMC: 3254708. DOI: 10.1016/j.neuroimage.2011.08.077. View

3.
Song N, Wang J, Jiang H, Xie J . Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease. Free Radic Biol Med. 2009; 48(2):332-41. DOI: 10.1016/j.freeradbiomed.2009.11.004. View

4.
Friedlich A, Tanzi R, Rogers J . The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol Psychiatry. 2007; 12(3):222-3. DOI: 10.1038/sj.mp.4001937. View

5.
Hardy J . Genetic analysis of pathways to Parkinson disease. Neuron. 2010; 68(2):201-6. PMC: 2997424. DOI: 10.1016/j.neuron.2010.10.014. View